Score Overview
Explore the 2021 public Archive ranking →
Where Lexicon Pharmaceuticals Inc has ranked, year by year
Showing 1 year ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- LXRX
2005: 48.0% · 2021: 95.0% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 1.88 | — |
1 Year2025-09-29 | $ 1.39 | 35.25% |
5 Years2021-09-29 | $ 4.91 | -61.71% |
10 Years2016-09-29 | $ 17.90 | -89.50% |
20 Years2006-09-29 | $ 26.39 | -92.88% |
All Time2000-04-07 | $ 131.25 | -98.57% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time2000-04-07 |
|---|---|---|---|---|---|---|
| Price | $ 1.88 | $ 1.39 | $ 4.91 | $ 17.90 | $ 26.39 | $ 131.25 |
| Return | — | 35.25% | -61.71% | -89.50% | -92.88% | -98.57% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 41M | -$ 61M | $ 190M |
| 2025 | $ 49M | -$ 50M | $ 96M |
| 2024 | $ 31M | -$ 200M | $ 237M |
| 2023 | $ 1M | -$ 177M | $ 170M |
| 2022 | -$ 101M | $ 138M | |
| 2021 | -$ 87M | $ 86M | |
| 2020 | $ 23M | -$ 58M | $ 152M |
| 2019 | $ 322M | $ 130M | $ 271M |
| 2018 | $ 63M | -$ 120M | $ 160M |
| 2017 | $ 90M | -$ 129M | $ 310M |
| 2016 | $ 83M | -$ 141M | $ 346M |
| 2015 | $ 130M | -$ 4M | $ 521M |
| 2014 | $ 22M | -$ 100M | $ 339M |
| 2013 | $ 2M | -$ 104M | $ 129M |
| 2012 | $ 1M | -$ 110M | $ 223M |
| 2011 | $ 1M | -$ 116M | $ 281M |
| 2010 | $ 4M | -$ 101M | $ 211M |
| 2009 | $ 10M | -$ 82M | $ 162M |
| 2008 | $ 32M | -$ 76M | $ 103M |
| 2007 | $ 50M | -$ 58M | $ 258M |
| 2006 | $ 72M | -$ 54M | $ 79M |
| 2005 | $ 75M | -$ 36M | $ 99M |
| 2004 | $ 61M | -$ 47M | $ 87M |
| 2003 | $ 42M | -$ 64M | $ 104M |
| 2002 | $ 35M | -$ 59M | $ 93M |
| 2001 | $ 305M | -$ 35M | $ 156M |
| IPO2000 | $ 14M | -$ 25M | $ 202M |
Lexicon Pharmaceuticals Inc fundamental performance
Between 2015 and 2025, revenue declined from $ 130M to $ 49M and net income went from -$ 4M to -$ 50M. Revenue increased in 6 of those 10 years; net income in 4.
Across Lexicon Pharmaceuticals Inc's full reported history, from 2000 to 2025, revenue grew from $ 14M to $ 49M and net income went from -$ 25M to -$ 50M. Revenue increased in 48% of the years measured; net income in 38%.
Lexicon Pharmaceuticals Inc currently holds a 20-year HDB Score of 2.2 out of 10. How the HDB Score is calculated.
Membership
Continue LXRX’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
